Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Sabestomig by AstraZeneca for Crohn's Disease (Regional Enteritis): Likelihood of Approval
Sabestomig is under clinical development by AstraZeneca and currently in Phase I for Crohn's Disease (Regional Enteritis). According to GlobalData,...
Sabestomig by AstraZeneca for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval
Sabestomig is under clinical development by AstraZeneca and currently in Phase II for Adenocarcinoma Of The Gastroesophageal Junction. According to...
Sabestomig by AstraZeneca for Gastric Cancer: Likelihood of Approval
Sabestomig is under clinical development by AstraZeneca and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II...
Risk adjusted net present value: What is the current valuation of AstraZeneca's Sabestomig?
Sabestomig is a monoclonal antibody commercialized by AstraZeneca, with a leading Phase II program in Gastric Cancer;Adenocarcinoma Of The Gastroesophageal...
Risk adjusted net present value: What is the current valuation of AstraZeneca's Sabestomig?
Sabestomig is a monoclonal antibody commercialized by AstraZeneca, with a leading Phase II program in Non-Small Cell Lung Carcinoma. According...